Philip Astley-Sparke
Founder at REPLIMUNE GROUP, INC.
Net worth: 8 M $ as of 2024-04-29
Philip Astley-Sparke active positions
| Companies | Position | Start | End |
|---|---|---|---|
| REPLIMUNE GROUP, INC. | Chairman | 2024-03-31 | - |
| Founder | 2015-02-28 | - | |
| Director/Board Member | 2015-02-28 | 2024-03-31 | |
| Chief Executive Officer | 2020-01-08 | 2024-03-31 | |
| Corporate Secretary | 2015-02-28 | - | |
| Treasurer | 2015-02-28 | - | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 2012-04-30 | - |
Replimune Ltd.
 Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Director/Board Member | 2015-03-17 | - |
Career history of Philip Astley-Sparke
Former positions of Philip Astley-Sparke
| Companies | Position | Start | End |
|---|---|---|---|
| UNIQURE N.V. | Director/Board Member | 2015-05-31 | 2016-09-21 |
| Chairman | 2016-09-21 | 2021-06-14 | |
| Independent Dir/Board Member | - | 2021-06-14 | |
| Corporate Officer/Principal | 2013-05-31 | 2016-09-21 | |
| Oxyrane, Ltd. | Chairman | 2011-12-31 | 2019-12-31 |
uniQure, Inc.
 uniQure, Inc. BiotechnologyHealth Technology Part of uniQure NV, uniQure, Inc. provides research and development services of human gene based therapies. The company is based in Lexington, MA. | President | 2012-12-31 | 2015-01-31 |
| AMGEN INC. | Corporate Officer/Principal | - | 2011-11-30 |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Chief Executive Officer | 2000-06-30 | 2011-03-30 |
| President | 2000-06-30 | 2011-03-30 | |
| FORN EUROPAR | Director/Board Member | - | - |
| Independent Dir/Board Member | - | - | |
| ░░░░░░ ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░ | ░░░░░░░░░░ | - |
Training of Philip Astley-Sparke
| University of Bristol | Undergraduate Degree |
Statistics
International
| United States | 7 |
| United Kingdom | 3 |
| Germany | 2 |
Operational
| Director/Board Member | 4 |
| Chief Executive Officer | 3 |
| President | 3 |
Sectoral
| Health Technology | 7 |
| Finance | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| UNIQURE N.V. | Health Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| Private companies | 7 |
|---|---|
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
| Oxyrane, Ltd. | |
Replimune Ltd.
Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Commercial Services |
Forbion European Acquisition Corp.
 Forbion European Acquisition Corp. Financial ConglomeratesFinance Forbion European Acquisition Corp. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded by Hugo Alexander Slootweg in 2006 and is headquartered in Wilmington, DE. | Finance |
uniQure, Inc.
uniQure, Inc. BiotechnologyHealth Technology Part of uniQure NV, uniQure, Inc. provides research and development services of human gene based therapies. The company is based in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Philip Astley-Sparke
- Experience
